Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   43209   clinical trials with a EudraCT protocol, of which   7151   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2014-000178-20
    Sponsor's Protocol Code Number:MCT8-2014-1
    National Competent Authority:Czechia - SUKL
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2015-06-23
    Trial results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedCzechia - SUKL
    A.2EudraCT number2014-000178-20
    A.3Full title of the trial
    Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial.
    Léčba pacientů s těžkou psychomotorickou retardací způsobenou mutací v
    MCT8 transportéru hormonu štítné žlázy analogem hormonu štítné žlázy:
    Studie Triac
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Therapy of MCT8 patients with the thyroid hormone analog Triac.
    Terapie MCT8 pacientů analogem hormonu štítné žlázy Triac
    A.3.2Name or abbreviated title of the trial where available
    Triac Trial in MCT8 patients
    Studie Triac u MCT8 pacientů
    A.4.1Sponsor's protocol code numberMCT8-2014-1
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT02060474
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorErasmus Medical Centre
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportZonMw
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationErasmus Medical Centre
    B.5.2Functional name of contact pointInformation Triac Trial
    B.5.3 Address:
    B.5.3.1Street AddressDr. Molenwaterplein 50
    B.5.3.2Town/ cityRotterdam
    B.5.3.3Post code3015 GE
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D. name Téatrois (Tiratricol)
    D. of the Marketing Authorisation holderLaboratoires Théranol-Deglaude
    D.2.1.2Country which granted the Marketing AuthorisationFrance
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTéatrois
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.
    Tato studie bude provedena u pacienta s Allan-Herndon-Dudley
    syndromem (AHDS), který je důsledkem mutace v transportéru pro
    thyroideální hormon (MCT8). Klinický fenotyp těchto pacientů zahrnuje
    těžkou psychomotorickou retardaci v důsledku hypothyroidismu v mozku
    v kombinaci s vysokou hladinou T3 a zvýšenou hladinou TSH, které
    vedou k hyperthyroidismu v tkáních, které MCT8 receptor neobsahují. To
    vede k tachykardii, nízké hmotnosti a svalové slabosti.
    E.1.1.1Medical condition in easily understood language
    Patients with a mutation in the thyroid hormone transporter MCT8, resulting in severe psychomotor retardation and abnormal thyroid hormone values in the blood.
    Pacienti s mutací v trasportéru hormonu štítné žlázy MCT8, která
    způsobuje psychomotorickou retardaci a abnormální hodnoty hormonů
    štítné žlázy v krvi.
    E.1.1.2Therapeutic area Diseases [C] - Hormonal diseases [C19]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    (1) To determine the effect of Triac treatment on serum T3 and other TH levels;
    (2) To determine the effect of Triac on the toxic effects of the hyperthyroid state in peripheral tissues;
    E.2.2Secondary objectives of the trial
    (1) To determine the effects of Triac treatment on the neurological phenotype.
    (2) The registration of adverse events
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    clinical relevant mutation in the MCT8 gene leading to the clinical phenotype of AHDS
    klinicky významná mutace v MCT8 genu vedoucí k fenotypu AHDS
    E.4Principal exclusion criteria
    - Major illness or recent major surgery (within 4 weeks) unrelated to AHDS
    - Patients who are participating in ongoing RCTs of therapeutic interventions (including clinical trials of investigational medicinal products);
    - Patients that have any major contra-indication for Triac treatment (severe cardiac decompensation (NYHA 4), coronary insufficiency, severe cardiac arrhytmias, Galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption)
    - závažné onemocnění či chirurgický výkon nesouvisející s AHDS
    - pacienti, kteří se účastní právě probíhajících RC studií léčebných
    výkonů (zahrnující klinické studie léčivých přípravků)
    - pacienti, kteří mají kontraindikace léčby přípravkem Triac (těžké
    srdeční selhání – NYHA4, koronární nedostatečností, těžké srdeční
    arytmie, intolerance galaktosy, intolerance laktosy, glukoso-galaktosová
    E.5 End points
    E.5.1Primary end point(s)
    1) Serum TSH, T4, vrij T4, T3, rT3 and Triac levels
    E.5.1.1Timepoint(s) of evaluation of this end point
    These primary endpoints will be evaluated at baseline (t=0) and after 1 year of Triac treatment.
    To optimize titration of the Triac dose and prevent overtreatment, primary end-points will be evaluated with an expected average of 2 weeks during months 1-3 of the trial. During months 4-12 these parameters will be evaluated with an expected average of 6 weeks.
    E.5.2Secondary end point(s)
    1) Body weight, blood pressure and heart rate
    2) Serum levels of markers that reflect peripheral thyroid hormone action: serum steroid hormone binding globuline (SHBG) and lipids (liver), serum beta Ctx and alkalisch phosphatase (bone) and serum kreatine kinase (muscle).
    3) Motor function, using the Gross Motor Function Measure
    4) Cognitive function using the Bayley Scales of Infant Development III, or Wechsler Preschool and Primary Scale of Intelligence II
    5) Adaptive behavior measured by the Vineland adaptive behavior scale
    6) Basal Metabolic Rate (BMR) using Doubly labeled Water (DLW)
    6) The frequency and nature of adverse events
    E.5.2.1Timepoint(s) of evaluation of this end point
    The secundary end points 1-3 will will be evaluated at baseline (t=0) and after 1 year of Triac treatment.
    To optimize titration of the Triac dose and prevent overtreatment, these end points will also be evaluated with an expected average of 2 weeks during months 1-3 of the trial. During months 4-12 these parameters will be evaluated with an expected average of 6 weeks.
    End points 3), 4) and 5) will be evaluated at baseline and after 1 year of Triac treatment.
    Point 6) will be evaluated during the whole study period.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA11
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    the end of the trial is defined as the date of the last investigational visit for the last patient undergoing protocol treatment.
    Konec studie je definovaný datem poslední návštěvy pacienta dle
    studijního protokolu
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months2
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 1
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F. of subjects for this age range: 1
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F. of subjects incapable of giving consent
    severe psychomotor retardation is part of the AHDS phenotype. Since this study is specifically conducted to evualute the effectiveness of the IMD in this population, the inclusion of this population is inevitable.
    těžká psychomotorická retardace je součástí AHDS fenotypu. Vzhledem
    k významu této studie je zařazení těchto pacientů nevyhnutelné.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state1
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 40
    F.4.2.2In the whole clinical trial 40
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    If Triac treatment turns out to be successfull, a second international trial will be conducted to assess the effects of Triac on the neurological phenotype in greater detail. Patients that participate in this trial will also be enrolled in this second study.
    In addition, the regular health care will be continued during the study period and will also be continued after the study will be ended.
    Pokud bude léčba preparátem Triac úspěšná,druhá mezinárodní studie
    k podrobnějšímu zhodnocení účinků Triac na neurologický fenotyp bude
    následovat. Pacienti, kteří se podílejí na první studii, budou zařazené
    také do studie druhé. Pravidelná zdravotní péče bude poskytnuta v
    průběhu sledovaného období a bude pokračovat i po ukončení studie.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-07-10
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-02-04
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice